Next Article in Journal
Course of Adverse Events during Short Treatment Regimen in Patients with Rifampicin-Resistant Tuberculosis in Burundi
Next Article in Special Issue
COVID-19 and Heart: From Clinical Features to Pharmacological Implications
Previous Article in Journal
Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies
Previous Article in Special Issue
Non-Overt Coagulopathy in Non-ICU Patients with Mild to Moderate COVID-19 Pneumonia
Article

Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories

1
Laboratoire de Virologie, Institut des Agents Infectieux (IAI), Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004 Lyon, France
2
Centre National de Référence des Virus Respiratoires, Hospices Civils de Lyon, Groupement Hospitalier Nord, 69004 Lyon, France
3
Laboratoire Commun de Recherche Hospices Civils de Lyon–bioMérieux, Centre Hospitalier Lyon Sud, 69310 Pierre-Bénite, France
4
Université de Lyon, Virpath, CIRI, INSERM U1111, CNRS UMR5308, ENS Lyon, Université Claude Bernard Lyon 1, F-69372 Lyon, France
*
Authors to whom correspondence should be addressed.
Equal contributions.
J. Clin. Med. 2020, 9(6), 1871; https://doi.org/10.3390/jcm9061871
Received: 24 April 2020 / Revised: 30 May 2020 / Accepted: 11 June 2020 / Published: 16 June 2020
(This article belongs to the Special Issue COVID-19: From Pathophysiology to Clinical Practice)
A reliable diagnostic assay is crucial to early detect new COVID-19 cases and limit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission. Since the onset of the COVID-19 pandemic, the World Health Organization has published several diagnostic molecular approaches developed by referral laboratories, including Charité (Germany), HKU (Hong Kong), China CDC (China), US CDC (United States), and Institut Pasteur, Paris (France). We aimed to compare the sensitivity and specificity of these different RT-PCR assays using SARS-CoV-2 cell culture supernatants and clinical respiratory samples. Overall, the different RT-PCR assays performed well for SARS-CoV-2 detection and were all specific except the N Charité (Germany), and N2 US CDC (United States) assays. RdRp Institut Pasteur (IP2, IP4), N China CDC, and N1 US CDC were found to be the most sensitive assays. The data presented herein are of prime importance to facilitate the equipment choice of diagnostic laboratories, as well as for the development of marketed tests. View Full-Text
Keywords: SARS-CoV-2; COVID-19; RT-PCR; diagnostics; sensitivity SARS-CoV-2; COVID-19; RT-PCR; diagnostics; sensitivity
Show Figures

Figure 1

MDPI and ACS Style

Etievant, S.; Bal, A.; Escuret, V.; Brengel-Pesce, K.; Bouscambert, M.; Cheynet, V.; Generenaz, L.; Oriol, G.; Destras, G.; Billaud, G.; Josset, L.; Frobert, E.; Morfin, F.; Gaymard, A. Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories. J. Clin. Med. 2020, 9, 1871. https://doi.org/10.3390/jcm9061871

AMA Style

Etievant S, Bal A, Escuret V, Brengel-Pesce K, Bouscambert M, Cheynet V, Generenaz L, Oriol G, Destras G, Billaud G, Josset L, Frobert E, Morfin F, Gaymard A. Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories. Journal of Clinical Medicine. 2020; 9(6):1871. https://doi.org/10.3390/jcm9061871

Chicago/Turabian Style

Etievant, Sibyle, Antonin Bal, Vanessa Escuret, Karen Brengel-Pesce, Maude Bouscambert, Valérie Cheynet, Laurence Generenaz, Guy Oriol, Gregory Destras, Geneviève Billaud, Laurence Josset, Emilie Frobert, Florence Morfin, and Alexandre Gaymard. 2020. "Performance Assessment of SARS-CoV-2 PCR Assays Developed by WHO Referral Laboratories" Journal of Clinical Medicine 9, no. 6: 1871. https://doi.org/10.3390/jcm9061871

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop